iRadimed (NASDAQ:IRMD) Issues Q3 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its third quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.540-0.590 for the period, compared to the consensus estimate of 0.530. The company issued revenue guidance of $23.0 million-$24.5 million, compared to the consensus revenue estimate of $23.7 million. iRadimed also updated its FY 2026 guidance to 2.090-2.240 EPS.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Trading Down 4.6%

Shares of IRMD traded down $4.35 during mid-day trading on Friday, reaching $90.86. 308,080 shares of the stock traded hands, compared to its average volume of 111,471. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90. iRadimed has a 1 year low of $57.83 and a 1 year high of $107.90. The firm has a fifty day moving average price of $94.54 and a 200 day moving average price of $95.70.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, sell-side analysts anticipate that iRadimed will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 43.72%.

Insider Activity

In other news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 21,250 shares of company stock worth $1,836,403. Company insiders own 34.60% of the company’s stock.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently made changes to their positions in IRMD. Quarry LP purchased a new stake in shares of iRadimed during the 3rd quarter valued at $40,000. Tower Research Capital LLC TRC lifted its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the last quarter. Virtus Advisers LLC purchased a new position in shares of iRadimed in the 3rd quarter worth about $117,000. Aquatic Capital Management LLC boosted its holdings in shares of iRadimed by 210,400.0% in the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after purchasing an additional 2,104 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of iRadimed during the 3rd quarter valued at about $164,000. Institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.